Aliases & Classifications for Neuritis

MalaCards integrated aliases for Neuritis:

Name: Neuritis 12 54 43 15 71
Peripheral Neuritis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1803
MeSH 43 D009443
NCIt 49 C116381
SNOMED-CT 67 128192007
UMLS 71 C0027813

Summaries for Neuritis

MalaCards based summary : Neuritis, also known as peripheral neuritis, is related to acute retrobulbar neuritis and autoimmune optic neuritis, and has symptoms including sciatica and neuralgia. An important gene associated with Neuritis is PMP2 (Peripheral Myelin Protein 2), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Acetylcholine and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include testes, eye and brain, and related phenotypes are behavior/neurological and cellular

Related Diseases for Neuritis

Diseases related to Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1107)
# Related Disease Score Top Affiliating Genes
1 acute retrobulbar neuritis 34.8 MT-ND4 MBP AQP4
2 autoimmune optic neuritis 34.4 MOG MBP AQP4
3 optic neuritis 33.5 TNF MT-ND4 MPZ MOG MBP MAG
4 amyotrophic neuralgia 33.3 SEPTIN9 PMP22 MPZ
5 neuromyelitis optica 33.0 MOG MBP IL6 IL4 IL1B GFAP
6 optic nerve disease 32.0 TNF MT-ND4 MOG MBP MAG IL6
7 allergic encephalomyelitis 31.8 MOG MBP CCL5
8 neuropathy 31.6 SEPTIN9 PMP22 PMP2 MT-ND4 MPZ
9 guillain-barre syndrome 31.3 TNF PMP22 PMP2 MPZ MOG MBP
10 herpes zoster 31.2 TNF IL10 IFNG
11 syphilis 31.2 TNF IL6 IFNG
12 myelitis 31.1 TNF MOG MBP IL6 IL10 AQP4
13 transverse myelitis 31.0 TNF MBP IL6 IL10 AQP4
14 measles 31.0 TNF IL6 IL1B IFNG CCL5
15 leprosy 3 30.9 TNF IL6 IL4 IL1B IL10 IFNG
16 lyme disease 30.9 TNF IL6 IL1B
17 macular retinal edema 30.9 TNF IL6 IL1B
18 iridocyclitis 30.9 TNF IL6 IL10
19 chickenpox 30.9 TNF IL6 IL4 IL10 IFNG
20 choroiditis 30.8 TNF IL10 IFNG
21 mononeuritis multiplex 30.8 TNF PMP22 MAG
22 polyneuropathy 30.8 TNF PMP22 MPZ MBP MAG IL6
23 cytomegalovirus retinitis 30.8 TNF IL10 IFNG
24 miller fisher syndrome 30.8 TNF PMP22 MAG AQP4
25 exanthem 30.8 TNF IL6 IL1B IL10 IFNG
26 chorioretinitis 30.8 TNF IL6 IL10 IFNG
27 internuclear ophthalmoplegia 30.7 MOG MBP AQP4
28 poliomyelitis 30.7 TNF IL4 IL10 IFNG
29 mumps 30.7 TNF IL6 IL1B IL10 IFNG
30 diphtheria 30.7 TNF IL4 IL1B IFNG
31 sarcoidosis 1 30.7 TNF IL1B IFNG CCL5 CCL4
32 acute disseminated encephalomyelitis 30.6 MPZ MOG MBP IL1B IL10 CCL4
33 brachial plexus neuropathy 30.6 SEPTIN9 PMP22 MPZ
34 mononeuropathy 30.6 TNF PMP22 MPZ MAG
35 sensory peripheral neuropathy 30.6 PMP22 MPZ MAG BDNF
36 typhoid fever 30.6 TNF IL6 IL1B IFNG
37 panuveitis 30.6 TNF IL6 IL10
38 pertussis 30.6 TNF IL6 IL1B IL10 CCL5
39 carpal tunnel syndrome 30.6 PMP22 MPZ IL6 IL1B
40 aseptic meningitis 30.6 TNF IL1B IL10 IFNG
41 spondylitis 30.6 TNF IL6 IL10 IFNG
42 keratitis, hereditary 30.5 TNF IL6 IL1B
43 neurilemmoma 30.5 PMP22 MPZ MBP GFAP
44 cytomegalovirus infection 30.5 TNF IL6 IL1B CCL5
45 acquired immunodeficiency syndrome 30.5 TNF MBP IL6 IL1B IL10 IFNG
46 neuroma 30.5 IL6 GFAP AQP4
47 posterior uveitis 30.5 TNF IL6 IL4 IFNG
48 myasthenia gravis 30.5 TNF MBP IL4 IL10 IFNG
49 influenza 30.5 TNF IL6 IL1B IFNG CCL5
50 neuropathy, hereditary, with liability to pressure palsies 30.5 PMP22 MPZ MAG

Graphical network of the top 20 diseases related to Neuritis:



Diseases related to Neuritis

Symptoms & Phenotypes for Neuritis

UMLS symptoms related to Neuritis:


sciatica, neuralgia

MGI Mouse Phenotypes related to Neuritis:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 AQP4 BDNF GFAP IFNG IL10 IL6
2 cellular MP:0005384 10.35 BDNF GFAP IFNG IL10 IL4 IL6
3 growth/size/body region MP:0005378 10.34 AQP4 BDNF GFAP IFNG IL10 IL1B
4 homeostasis/metabolism MP:0005376 10.33 AQP4 BDNF GFAP IFNG IL10 IL1B
5 hematopoietic system MP:0005397 10.32 AQP4 CCL5 IFNG IL10 IL1B IL4
6 immune system MP:0005387 10.31 AQP4 CCL5 GFAP IFNG IL10 IL1B
7 mortality/aging MP:0010768 10.21 AQP4 BDNF GFAP IFNG IL10 IL1B
8 nervous system MP:0003631 10.16 AQP4 BDNF GFAP IFNG IL10 IL1B
9 digestive/alimentary MP:0005381 10.11 AQP4 BDNF GFAP IFNG IL10 IL4
10 craniofacial MP:0005382 10.07 BDNF IFNG IL10 IL1B IL4 MAPT
11 integument MP:0010771 10.06 BDNF IFNG IL10 IL1B IL4 IL6
12 muscle MP:0005369 9.92 GFAP IFNG IL10 IL6 MAPT MOG
13 no phenotypic analysis MP:0003012 9.7 AQP4 BDNF IFNG IL10 IL4 MAPT
14 respiratory system MP:0005388 9.56 AQP4 BDNF IFNG IL10 IL4 IL6
15 vision/eye MP:0005391 9.4 AQP4 BDNF GFAP IFNG IL10 IL4

Drugs & Therapeutics for Neuritis

Drugs for Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6
4-Aminopyridine Approved Phase 4 504-24-5 1727
7
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
8
rituximab Approved Phase 4 174722-31-7 10201696
9 Integrase Inhibitors Phase 4
10 Anti-HIV Agents Phase 4
11 HIV Integrase Inhibitors Phase 4
12 Raltegravir Potassium Phase 4
13 Anti-Retroviral Agents Phase 4
14 (T,G)-A-L Phase 4
15
Glatiramer Acetate Phase 4 147245-92-9 3081884
16
protease inhibitors Phase 4
17 HIV Protease Inhibitors Phase 4
18 Anesthetics Phase 4
19 Cholinergic Agents Phase 4
20 Botulinum Toxins Phase 4
21 Anesthetics, Local Phase 4
22 BB 1101 Phase 4
23 Antineoplastic Agents, Hormonal Phase 4
24 Potassium Channel Blockers Phase 4
25 Respiratory System Agents Phase 4
26 Anti-Asthmatic Agents Phase 4
27 Antineoplastic Agents, Immunological Phase 4
28 Adrenocorticotropic Hormone Phase 4
29 Melanocyte-Stimulating Hormones Phase 4
30 beta-Endorphin Phase 4
31
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
32
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
33
Ravulizumab Approved, Investigational Phase 3 1803171-55-2
34
Interferon beta-1b Approved Phase 2, Phase 3 145155-23-3
35 Ginkgo Phase 3
36 Analgesics, Non-Narcotic Phase 2, Phase 3
37 Cyclooxygenase Inhibitors Phase 2, Phase 3
38 Analgesics Phase 2, Phase 3
39 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
40 Complement System Proteins Phase 3
41 Hematinics Phase 3
42 Epoetin alfa Phase 3 113427-24-0
43 Fingolimod Hydrochloride Phase 2, Phase 3
44 Immunoglobulins Phase 3
45 Antibodies Phase 3
46 Vaccines Phase 3
47
Hydrochlorothiazide Approved, Vet_approved Phase 2 58-93-5 3639
48
Amiloride Approved Phase 2 2016-88-8, 2609-46-3 16231
49
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
50
Coal tar Approved Phase 1, Phase 2 8007-45-2

Interventional clinical trials:

(show top 50) (show all 161)
# Name Status NCT ID Phase Drugs
1 An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir(RAL)in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
2 A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS Unknown status NCT00910598 Phase 4 glatiramer acetate
3 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4 Prednisolone
4 Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10) Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
5 Probe Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome Completed NCT00241215 Phase 4 Botulinum toxin serotype A
6 Combination of Dexamethasone and Bupivacaine Versus Bupivacaine Alone in Combined Femoral and Sciatic Nerve Block for Intraoperative and Postoperative Analgesia in Patients Undergoing Lower Limb Vascular Surgeries Completed NCT02576782 Phase 4 Perineural Dexamethasone and bupivacaine;Systemic Dexamethasone plus perineural bupivacaine;intravenous saline plus perineural bupivacaine
7 Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation Recruiting NCT03247413 Phase 4 Dexamethasone 4 mg/ml;Normal saline
8 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Recruiting NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV methylprednisolone (steroids)
9 Acute Unilateral Vestibulopathy and Corticosteroid Treatment Recruiting NCT02912182 Phase 4 Betamethasone;Placebo;Prednisolone
10 Short and Long Term Fampridine Treatment in Persons With Multiple Sclerosis: Cognitive and Motor Performances Recruiting NCT02849782 Phase 4 Fampridine
11 Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE): a Prospective, Multicenter, Open-label, Follow-up Clinical Trial Active, not recruiting NCT04256252 Phase 4 Rituximab
12 Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis Terminated NCT00854750 Phase 4 ACTHAR;ACTHAR;ACTHAR;ACTHAR
13 Optical Coherence Tomography as a Measure of Neuroprotection in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Natalizumab or Interferon Beta-1a Withdrawn NCT00771043 Phase 4 TYSABRI and AVONEX
14 An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
15 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study Unknown status NCT02220244 Phase 3 MD1003 100mg capsule
16 Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial Unknown status NCT00261326 Phase 3 simvastatin;placebo
17 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
18 Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Completed NCT01962571 Phase 3 Erythropoietin alfa;Placebo
19 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON) Completed NCT00856635 Phase 3 Glatiramer Acetate;placebo
20 The Efficacy of Steroid Therapy in Vestibular Neuritis Confirmed by Head Impulse Test: Prospective Randomized Controlled Study Completed NCT02098330 Phase 3 Ginkgo biloba & Methylprednisolone;Ginkgo biloba
21 Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis Completed NCT01337986 Phase 2, Phase 3 Dalfampridine/Placebo;Placebo/Dalfampridine
22 Recovery of Demyelinating Optic Neuritis After Treatment With Equivalent High Doses of Oral vs. Intravenous Corticosteroids: a Randomized Single Blinded Clinical Trial Completed NCT01524250 Phase 2, Phase 3 corticosteroids;corticosteroids
23 A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Multifocal Motor Neuropathy Completed NCT00666263 Phase 3
24 Intravenous Immunoglobulin Therapy in Optic Neuritis Completed NCT00000117 Phase 3 Immunoglobulin
25 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Multifocal Motor Neuropathy. Completed NCT01827072 Phase 3 NPB-01
26 Hypoalgesic Effect of Median Nerve Neural Mobilization Versus Ibuprofen Pharmacologic Treatment in Patients With Cervicobrachial Pain Completed NCT02593721 Phase 2, Phase 3 Ibuprofen
27 Comparison of Annual Relapse Rate, Expanded Disability Status Scale, and Side Effects Between Azathioprine and Rituximab in Patients With Neuromyelitis Optica Spectrum Disorders Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
28 Effects of Dalfampridine on Cognition in Multiple Sclerosis Completed NCT02006160 Phase 2, Phase 3 dalfampridine;placebo
29 A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) Recruiting NCT04201262 Phase 3
30 A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum Disorder Recruiting NCT04155424 Phase 2, Phase 3 Eculizumab
31 A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) Active, not recruiting NCT02003144 Phase 3
32 Erythropoietin in Methanol Associated Optic Neuropathy Active, not recruiting NCT02376881 Phase 3 Erythropoietin
33 Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis Terminated NCT01647880 Phase 2, Phase 3 Verum arm receiving Gilenya®;Active Comparator receiving Extavia®
34 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) Terminated NCT01892345 Phase 3 Eculizumab;Placebo
35 The Investigation Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography Unknown status NCT01465893 Phase 2 Vitamin D;Vitamin D withheld
36 Gypenosides Treatment for Optic Neuritis: a Randomised, Double-blind, Placebo-controlled Trial Unknown status NCT02976766 Phase 2 Gypenosides;Placebo
37 A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis Unknown status NCT01879527 Phase 2 Amiloride hydrochlorothiazide;Sugar pill
38 Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
39 A Randomised, Double-blind, Placebo-controlled Study of AIMSPRO in Treating Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
40 Hyperbaric Oxygen Treatment of Mandibular Osteoradionecrosis. A Randomized Clinical Study Unknown status NCT00760682 Phase 2
41 A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis Completed NCT01721161 Phase 2 Placebo
42 A Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic Neuritis Completed NCT01802489 Phase 2 Amiloride;Placebo
43 Visual Reconstitution Therapy After Optic Neuritis Completed NCT01274702 Phase 2
44 a Phase II Double Blind, Randomized, Placebo Controlled Trial of Effect of Phenytoin on the Ganglion Cell Inner Plexiform Layer (GCIPL) Thickness and Visual Field in Patients With a First Episode of Acute Optic Neuritis Completed NCT02939937 Phase 2 Phenytoin;placebo
45 A Phase II Double Blind, Randomized, Placebo Controlled Trial of Neuroprotection With Phenytoin in Acute Optic Neuritis Completed NCT01451593 Phase 2 Phenytoin;Placebo
46 A Multicenter, Follow-Up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201 Completed NCT02657915 Phase 2 Placebo;BIIB033 100mg/Kg
47 A Multicentre Study of Subcutaneous Immunoglobulin (SCIG) in Patients With Multifocal Motor Neuropathy (MMN) Completed NCT00701662 Phase 2
48 Double Blind, Placebo-controlled Study to Determine the Safety and Efficacy of Erythropoietin as an add-on Therapy of Methylprednisolone in Subjects With Acute Optic Neuritis (VISION PROTECT) Completed NCT00355095 Phase 2 Erythropoietin
49 Autologous Adult Human Mesenchymal Stem Cells: a Neuroprotective Therapy for Multiple Sclerosis Completed NCT00395200 Phase 1, Phase 2
50 A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis Completed NCT00772525 Phase 2 Nerispirdine;Placebo

Search NIH Clinical Center for Neuritis

Cochrane evidence based reviews: neuritis

Genetic Tests for Neuritis

Anatomical Context for Neuritis

MalaCards organs/tissues related to Neuritis:

40
Testes, Eye, Brain, T Cells, Spinal Cord, Bone, Retina

Publications for Neuritis

Articles related to Neuritis:

(show top 50) (show all 10147)
# Title Authors PMID Year
1
Alpha- and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes. 61 54
18577885 2008
2
Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease. 54 61
16753180 2006
3
Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. 61 54
16519780 2006
4
Guillain-Barré syndrome. 61 54
16271648 2005
5
Sequential expression of chemokines in experimental autoimmune neuritis. 61 54
11024541 2000
6
Pathogenesis of Guillain-Barré syndrome. 61 54
10695718 1999
7
Induction of experimental autoimmune neuritis with peripheral myelin protein-22. 61 54
9798745 1998
8
Clomipramine and imipramine suppress clinical signs and T and B cell response to myelin proteins in experimental autoimmune neuritis in Lewis rats. 54 61
9776709 1998
9
Effect of lipids on the conformation of an antigenic determinant for experimental autoimmune neuritis. 61 54
9584990 1998
10
Antigen therapy eliminates T cell inflammation by apoptosis: effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2. 54 61
9037054 1997
11
The antibody repertoire in experimental allergic neuritis: evidence for PMP-22 as a novel neuritogen. 61 54
8982118 1996
12
Conformation of an antigenic determinant for experimental autoimmune neuritis. 61 54
8694832 1996
13
Human peripheral myelin protein-22 carries the L2/HNK-1 carbohydrate adhesion epitope. 61 54
7693873 1993
14
Pathogenesis of immune-mediated neuropathies. 54 61
8381954 1993
15
Shared T-cell receptor gene usage in experimental allergic neuritis and encephalomyelitis. 54 61
1381167 1992
16
[Immunoregulation disturbance in experimental allergic neuritis. The cellular and humoral mediated immunological damage]. 54 61
1711438 1990
17
Macrophages but not Schwann cells express Ia antigen in experimental autoimmune neuritis. 61 54
2375636 1990
18
Neuroprotection mediated by natural products and their chemical derivatives. 61
32394948 2020
19
Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. 61
32576604 2020
20
Papulonecrotic tuberculid with optic neuritis. 61
32445311 2020
21
Return to sporting activity after ulnar nerve transposition for isolated neuritis in competitive overhead athletes. 61
32418855 2020
22
Ulnar Collateral Ligament Reconstruction. 61
32446572 2020
23
Optic neuritis in German children: clinical findings and association with multiple sclerosis. 61
32274587 2020
24
Acute vestibular syndrome and hearing loss mimicking labyrinthitis as initial presentation of multiple sclerosis. 61
32353617 2020
25
Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease? 61
32361664 2020
26
Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors. 61
32461353 2020
27
Diagnostic features of initial demyelinating events associated with serum MOG-IgG. 61
32442864 2020
28
Optic nerve atrophy and whole and regional brain atrophy in Leber's hereditary optic neuropathy with multiple sclerosis-like disease with m.11778G>A mutation. 61
32387972 2020
29
Atypical Manifestations of Cat-Scratch Disease, United States, 2005-2014. 61
32568056 2020
30
Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study. 61
32424064 2020
31
Initial Degree of Spontaneous Nystagmus Affects the Length of Hospitalization of Patients With Vestibular Neuritis. 61
32332452 2020
32
Active Surveillance of Adverse Events Following Human Papillomavirus Vaccination: Feasibility Pilot Study Based on the Regional Health Care Information Platform in the City of Ningbo, China. 61
32234696 2020
33
Multimodal imaging of secondary vitreoretinal lymphoma with optic neuritis and retinal vasculitis. 61
32322750 2020
34
Herpes Simplex Virus 2 Meningoencephalitis-Associated Bilateral Optic Neuritis and Radiculitis. 61
32395172 2020
35
Toxocariasis of the Nervous System. 61
31960218 2020
36
Neurological phenotypes in patients with NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants. 61
32563262 2020
37
Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13. 61
32570180 2020
38
Unilateral Optic Neuritis in Children: Experience of a Tertiary Centre. 61
32570233 2020
39
Vision Loss from Atypical Optic Neuritis: Patient and Physician Perspectives. 61
32200476 2020
40
Recurrent MOG-IgG optic neuritis initially attributed to Sjögren's syndrome. 61
32522294 2020
41
Optimization of spectral domain optical coherence tomography and visual evoked potentials to identify unilateral optic neuritis. 61
32092503 2020
42
Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders. 61
32179485 2020
43
Bilateral optic neuritis as a complication of successive Flaviviridae virus infections. 61
31874710 2020
44
Seven-year nationwide incidence of optic neuritis requiring intravenous methylprednisolone injection in Korean adults. 61
31833213 2020
45
MOG-Ab prevalence in optic neuritis and clinical predictive factors for diagnosis. 61
31582363 2020
46
"NMDA receptor spectrum disorder" in the differential diagnosis of demyelinating disorders of the CNS: optic neuritis and myelitis. 61
32564271 2020
47
Combined central and peripheral demyelination with tumefactive demyelinating lesions in the brainstem and longitudinally extensive optic neuritis: a case report. 61
31872355 2020
48
Isolated cranial neuritis of the oculomotor nerve: Expanding the MOG phenotype? 61
32182468 2020
49
Ultrastructural characterization of mitochondrial damage in experimental autoimmune neuritis. 61
32251941 2020
50
Inflammatory oedema of nerve trunks may be pathogenic in very early Guillain-Barré syndrome. 61
32557265 2020

Variations for Neuritis

Expression for Neuritis

Search GEO for disease gene expression data for Neuritis.

Pathways for Neuritis

Pathways related to Neuritis according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 TNF IL6 IL4 IL1B IL10 IFNG
2
Show member pathways
13.59 TNF IL6 IL4 IL1B IL10 IFNG
3
Show member pathways
13.45 TNF IL6 IL4 IL1B IL10 CCL5
4
Show member pathways
13.4 TNF IL6 IL4 IL1B IL10 IFNG
5
Show member pathways
13.34 TNF IL6 IL4 IL1B IL10 CCL5
6
Show member pathways
13.1 TNF IL6 IL1B IL10 IFNG CCL5
7
Show member pathways
12.9 TNF IL6 IL4 IL1B IL10 IFNG
8
Show member pathways
12.84 TNF IL6 IL1B IFNG CCL5
9 12.82 TNF IL6 IL1B IFNG CCL5
10
Show member pathways
12.65 TNF IL6 IL4 IL1B IL10 IFNG
11
Show member pathways
12.64 TNF IL6 IL4 IL1B IL10 IFNG
12
Show member pathways
12.63 TNF IL6 IL1B IL10 IFNG
13 12.6 TNF IL4 IL1B IL10 IFNG CCL5
14
Show member pathways
12.5 IL6 IL4 IL10 IFNG GFAP
15 12.42 TNF SEPTIN9 IL1B CCL5
16
Show member pathways
12.39 TNF IL6 IL4 IL1B IFNG
17
Show member pathways
12.38 TNF IL6 IL10 CCL5 CCL4
18
Show member pathways
12.35 TNF IL6 IL4 IL1B IFNG CCL5
19
Show member pathways
12.32 TNF IL4 IL1B IL10 IFNG
20 12.29 TNF IL6 IL1B IL10 IFNG
21 12.28 TNF IL6 IL1B CCL5
22
Show member pathways
12.26 TNF IL6 IL4 IL1B IL10 IFNG
23
Show member pathways
12.25 TNF IL6 IL1B IL10
24
Show member pathways
12.23 TNF IL6 IL4 IL1B IFNG
25 12.14 TNF IL6 IL1B IL10 BDNF AQP4
26 12.07 TNF IL6 IL1B IL10
27 12.05 TNF IL6 IL4 IL10 IFNG
28
Show member pathways
12.04 IL4 IL1B IFNG CCL4
29 12.04 TNF IL6 IL4 IL1B IL10
30 12.03 TNF IL6 IL1B CCL5
31
Show member pathways
11.99 TNF IL6 IL1B IL10 IFNG
32 11.98 PMP22 MPZ MBP GFAP
33 11.96 TNF IL6 IL4 IL1B
34 11.95 TNF IL6 IL1B IL10 IFNG
35
Show member pathways
11.92 IL6 IL4 IL1B IFNG
36 11.89 TNF IL6 IL1B IFNG CCL5
37 11.83 IL6 IL4 IFNG
38 11.83 TNF IL6 IL1B IL10
39 11.8 MOG GFAP BDNF
40 11.8 TNF IL4 IL1B IL10 IFNG
41
Show member pathways
11.78 TNF IL4 IFNG
42 11.74 TNF IL6 IL1B IL10 IFNG
43
Show member pathways
11.72 TNF IL6 IL1B IFNG
44 11.69 MBP MAG BDNF
45 11.65 TNF IL6 IL1B
46 11.6 TNF IL6 IFNG
47 11.6 TNF IL6 IL4 IL1B CCL5 CCL4
48 11.57 TNF IL1B IFNG
49 11.57 TNF IL1B IFNG
50 11.55 IL4 IL10 IFNG

GO Terms for Neuritis

Cellular components related to Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.91 TNF IL6 IL4 IL1B IL10 IFNG
2 extracellular region GO:0005576 9.9 TNF MAPT IL6 IL4 IL1B IL10
3 astrocyte end-foot GO:0097450 9.32 GFAP AQP4
4 myelin sheath GO:0043209 9.26 PMP2 MPZ MBP MAG
5 compact myelin GO:0043218 8.8 PMP22 MBP MAG

Biological processes related to Neuritis according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.11 TNF IL6 IL4 IL1B IFNG
2 inflammatory response GO:0006954 10.08 TNF IL6 IL1B CCL5 CCL4
3 cell-cell signaling GO:0007267 10.02 MAPT IL1B CCL5 CCL4
4 cellular response to lipopolysaccharide GO:0071222 9.98 TNF IL6 IL1B IL10
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.9 TNF IL6 IL1B IL10
6 neutrophil chemotaxis GO:0030593 9.89 IL1B CCL5 CCL4
7 response to virus GO:0009615 9.89 TNF IFNG CCL5 CCL4
8 cellular response to organic cyclic compound GO:0071407 9.88 TNF IL1B CCL5
9 negative regulation of neuron projection development GO:0010977 9.88 PMP22 MAG GFAP
10 response to glucocorticoid GO:0051384 9.88 TNF IL6 IL10
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 TNF IL6 CCL5
12 humoral immune response GO:0006959 9.87 TNF IL6 IFNG
13 cytokine-mediated signaling pathway GO:0019221 9.87 TNF IL6 IL4 IL1B IL10 CCL5
14 myelination GO:0042552 9.86 PMP22 MPZ MBP
15 positive regulation of interleukin-6 production GO:0032755 9.86 TNF IL6 IL1B
16 regulation of insulin secretion GO:0050796 9.86 TNF IL1B IFNG CCL5
17 positive regulation of T cell proliferation GO:0042102 9.83 IL6 IL4 IL1B CCL5
18 positive regulation of phagocytosis GO:0050766 9.82 TNF IL1B IFNG
19 monocyte chemotaxis GO:0002548 9.82 IL6 CCL5 CCL4
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.81 TNF IL1B IFNG
21 protein kinase B signaling GO:0043491 9.8 TNF IL1B CCL5
22 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 TNF IL6 IL4 IFNG CCL5
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.79 TNF IL1B CCL5
24 positive regulation of cytokine secretion GO:0050715 9.78 TNF IL10 IFNG
25 positive regulation of interleukin-6 secretion GO:2000778 9.78 TNF MBP IL1B IFNG
26 negative regulation of neurogenesis GO:0050768 9.76 TNF IL6 IL1B
27 positive regulation of JAK-STAT cascade GO:0046427 9.76 TNF IL6 IL10 CCL5
28 microglial cell activation GO:0001774 9.73 TNF MAPT IL4 IFNG
29 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.72 IL4 IL10
30 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.72 MBP IL10
31 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.72 TNF IL1B IFNG
32 negative regulation of amyloid-beta clearance GO:1900222 9.71 TNF IFNG
33 negative regulation of lipid storage GO:0010888 9.71 TNF IL6
34 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.71 TNF IFNG
35 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 TNF IL1B IL10
36 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B
37 endothelial cell apoptotic process GO:0072577 9.7 TNF IL10
38 positive regulation of neuroinflammatory response GO:0150078 9.69 TNF IL6 IL1B
39 positive regulation of natural killer cell chemotaxis GO:2000503 9.68 CCL5 CCL4
40 positive regulation of mononuclear cell migration GO:0071677 9.67 TNF IL4
41 type 2 immune response GO:0042092 9.67 IL4 IL10
42 negative regulation of cytokine production involved in immune response GO:0002719 9.67 TNF IL10
43 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IL4 IL10 IFNG
44 positive regulation of cellular respiration GO:1901857 9.66 IL4 IFNG
45 neuroinflammatory response GO:0150076 9.66 IL4 IFNG
46 positive regulation of fever generation GO:0031622 9.65 TNF IL1B
47 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 TNF IL10
48 regulation of isotype switching GO:0045191 9.63 IL4 IL10
49 sequestering of triglyceride GO:0030730 9.63 TNF IL1B
50 receptor biosynthetic process GO:0032800 9.61 TNF IL10

Molecular functions related to Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR5 chemokine receptor binding GO:0031730 9.26 CCL5 CCL4
2 growth factor activity GO:0008083 9.26 IL6 IL4 IL10 BDNF
3 cytokine activity GO:0005125 9.23 TNF IL6 IL4 IL1B IL10 IFNG
4 CCR1 chemokine receptor binding GO:0031726 9.16 CCL5 CCL4

Sources for Neuritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....